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the German Centeulmonary hypertension (PH), a common complication of left heart diseases (LHD), negatively impacts symptoms,
exercise capacity, and outcome. Although the true prevalence of PH-LHD is unknown, a subset of patients might
present signiﬁcant PH that cannot be explained by a passive increase in left-sided ﬁlling pressures. The term
“out-of-proportion” PH has been used to identify that population without a clear deﬁnition, which has been found less
than ideal and created confusion. We propose a change in terminology and a new deﬁnition of PH due to LHD. We
suggest to abandon “out-of-proportion” PH and to distinguish “isolated post-capillary PH” from “post-capillary PH
with a pre-capillary component” on the basis of the pressure difference between diastolic pulmonary artery pressure
and pulmonary artery wedge pressure. Although there is no validated treatment for PH-LHD, we provide insights into
management and discuss completed and randomized trials in this condition. Finally, we provide recommendations
for future clinical trials to establish safety and efﬁcacy of novel compounds to target this area of unmet medical need.
(J Am Coll Cardiol 2013;62:D100–8) ª 2013 by the American College of Cardiology FoundationPulmonary hypertension (PH) is a common complication of
left heart disease (LHD), frequently occurring as a “symptom”
of the underlying condition (1,2) and often related to disease
severity. Pulmonary hypertension LHD is most common in
patients with heart failure (HF), with preserved or reduced
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ance and exerts a negative impact on outcome (1–3). Over
the past 10 years, PH-LHD has been recognized as a growing
problem in terms of deﬁnition and differential diagnosis but
also of inﬂuence on outcome and therapy. Indeed, the
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Abbreviations
and Acronyms
CO = cardiac output
Cpc-PH = combined post-
capillary and pre-capillary PH
DPD = diastolic pressure
difference
EF = ejection fraction
HF = heart failure
HF-pEF = heart failure with
preserved ejection fraction
LHD = left heart disease
LV = left ventricle/
ventricular
mPAP = mean pulmonary
artery pressure
NO = nitric oxide
PAH = pulmonary arterial
hypertension
PCWP = pulmonary capillary
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D101often challenging in patients with heart failure with preserved
ejection fraction (HF-pEF). Compared with pulmonary
arterial hypertension (PAH), patients with PH-LHD are
more often older, female, with a history of systemic hyper-
tension (4), andmost, if not all, of the features of themetabolic
syndrome (5).
The true prevalence of PH-LHD inHF remains unknown,
due at least in part to the following: 1) current data are derived
from either epidemiological studies in community-based HF
populations (6–8) or tertiary HF referral centers (3); 2) the
deﬁnition of PH was based on echocardiography, with
a variety of cutoff values (6–8); 3) populations have been
heterogeneous, in terms of symptoms, age, and level of EF;
and 4) measurements of pulmonary arterial and left atrial
ﬁlling pressures were not assessed by right (RHC) and/or left
heart catheterization, with the exception of single-center
reports (3–5). As a result, the prevalence of PH in LHD has
been reported to range between 25% and 100% of the patients
studied (Table 1).
This paper provides new hemodynamic deﬁnitions,
terminology, and treatment insights of PH-LHD.
wedge pressure
PAWP = pulmonary artery
wedge pressure
PDE5 = phosphodiesterase
type 5
PH = pulmonary
hypertension
PVD = pulmonary vascular
disease
PVR = pulmonary vascular
resistance
RCT = randomized controlled
trial
RHC = right heart
catheterization
RV = right ventricle
sGC = soluble guanylate
cyclase
SV = stroke volume
TPG = transpulmonary
gradient
VO2 = oxygen consumptionDeﬁnitions and Terminology
The current hemodynamic deﬁnition of PH-LHD combines a
mean pulmonary artery pressure (mPAP) 25 mm Hg,
a pulmonary artery wedge pressure (PAWP)>15mmHg, and
a normal or reduced cardiac output (CO) (9). The trans-
pulmonary pressure gradient (TPG) (i.e., the difference
between mPAP and PAWP) is commonly used to distinguish
“passive” PH (TPG 12 mm Hg) from “reactive” PH (TPG
>12 mm Hg). However, this deﬁnition and the associated
terminology have been unsatisfactory, to such extent that “out-
of-proportion” PH-LHD has been often used to characterize
a subset of patients with signiﬁcant changes in the pulmonary
circulation.
There are several reasons why we need a simple and
workable deﬁnition for “out-of-proportion” PH in the
context of LHD.
Understanding the determinants of PH-LHD. Irres-
pective of the origin of left heart disease, the ﬁrst event leading
to PH is a passive backward transmission of ﬁlling pressures,
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Manuscript received October 12, 2013; accepted October 22, 2013.(10,11). The resulting increase in
PAWP might be enhanced by
exercise-induced mitral regurgi-
tation, together with a loss of
left atrial compliance (12). The
pulsatile load imposed by a chron-
ically elevated PAWP might also
play a role in the development of
PH (13). In some patients, these
purely mechanical components of
venous congestion might trigger
a superimposed component,
combining pulmonary vasocon-
striction, decreased nitric oxide
(NO) availability, increased
endothelin expression, desensiti-
zation to natriuretic peptide
induced vasodilation, and vascular
remodeling (2,14). At this stage,
mPAP increases further, and this
increase seems to be in excess of
the elevation of PAWP (10,11).
Finally, these changes might lead
to pulmonary vascular disease,
increased right ventricle (RV)
afterload, and RV failure (Fig. 1).
Heterogeneity in terms of
deﬁnition and terminology.
Many legitimate attempts to
distinguish the mechanical from
the active component have been
made, by using different terms
such as passive versus reactive,
ﬁxed versus irreversible, unre-
sponsive versus responsive, and
out of proportion versus propor-
tionate (1). These lead to unclear
deﬁnitions, especially because the
current deﬁnition of “passive”
versus “reactive” PH (9) has been
progressively substituted by “out-
of-proportion” PH. This term
has never been deﬁned by any
clear hemodynamic criteria, although it has been assumed
that PH develops “out-of-proportion” to the raised PAWP.
Areas of confusion with PAH/pre-capillary PH. The lack
of a clear deﬁnition of “out-of-proportion” PH causes
confusion with PAH. As a result, it might encourage
physicians to treat some patients suffering from PH-LHD
with PAH-approved therapies, despite the lack of evidence
(9). In contrast, complex surgery (transplantation, LV assist
device, valve surgery) might be considered too high risk
because of signiﬁcant PH. Finally, vasoreactivity testing in
PH-LHD is often performed without clear guidelines about
which vasodilator should be used to perform testing and the
expected changes in pulmonary vascular resistance (PVR)
Table 1 Prevalence of PH in HF (Selected Studies)
First Author
(Ref. #) n Type Deﬁnition of PH Population EF
% Measurable
TRV
Prevalence
of PH
Corrected
Prevalence of PH
Bursi (8)* 1,049 Echocardiography TTGþRAP
35 mm Hg
Epidemiological 91% 79% 72%
Damy (51)* 1,380 Echocardiography TTG 35 mm Hg Hull HF clinic 26% preserved 26% 25% 7%
Lam (7)y 244 Echocardiography TTGþRAP
35 mm Hg
Olmsted County
HF survey
Only EF 50% 83% 83% 69%
Leung (52)y 455 Invasive mPAP 25
LVEF 15%
Cath lab 52%
Robbins (5)y 122 Invasive mPAP 25
PAWP >15
PH reference
center
Mixed NA 23% 20%
See text for references. *All-comer patients with heart failure (HF); ypatients from HF/pulmonary hypertension (PH) specialized centers.
Cath lab ¼ catheterization laboratory; EF ¼ ejection fraction; mPAP ¼mean pulmonary artery pressure; PAWP ¼ pulmonary artery wedge pressure; RAP ¼ right atrial pressure (estimated from the inferior
vena cava); TRV ¼ tricuspid regurgitant jet velocity; TTG ¼ transtricuspid gradient.
Vachiéry et al. JACC Vol. 62, No. 25, Suppl D, 2013
Pulmonary Hypertension Due to Left Heart Diseases December 24, 2013:D100–8
D102and/or TPG. As a consequence this might lead to the
inappropriate use of PAH drug therapies.
Identiﬁcation of different hemodynamic presentations.
A simple way to clarify the deﬁnition would be to rely on
a simple description of the potential hemodynamic presen-
tations, as follows: 1) an elevated PAWP, but no signiﬁcant
change in the pulmonary circulation (i.e., absence of
pulmonary vascular disease or vascular remodeling) (PVD);
2) an elevated PAWP, with PVD; 3) a previously elevated
but meanwhile normalized PAWP, with persistence of
PVD. The latter can be found in patients who have
undergone forced diuresis in the presence of HF-pEF, atrial
ﬁbrillation and corrected valve disease.
A key issue is how to best describe “pulmonary vascular
disease” or the “pre-capillary remodeling component” (and
possibly also a “post-capillary remodeling component”) of an
initially purely passive phenomenon. In other words, how
can we deﬁne a change in the pulmonary circulation that
is not in relation with the increase in PAWP and that is
measurable by RHC? Some key characteristics of such
variables include the following: 1) it should reﬂect changes
of the pulmonary circulation and be a clear marker of PVD;Figure 1
Mechanism of Pulmonary Hypertension Due to
Left Heart Disease2) it must be less dependent on (or as independent as
possible of) the change in PAWP; 3) it should be minimally
inﬂuenced by changes in blood ﬂow and stroke volume (SV);
and 4) it should reﬂect changes in compliance and take
into account the distensibility of the pulmonary arteries.
Pulmonary vascular resistance, TPG, and the diastolic
pressure difference (DPD) (deﬁned as diastolic PAPdmean
PAWP) have the advantage of being easily obtained from
RHC. They might not all be suitable to describe the pre-
capillary component of PH-LHD. The PVR is commonly
used in clinical practice. It has the disadvantage of being
a composite variable, with an interdependent numerator and
denominator (changes in ﬂow inﬂuence pressure in the
pulmonary circulation). Therefore, it is highly sensitive to
changes in both ﬂow and ﬁlling pressures but does not
reﬂect changes in the pulmonary circulation at rest (11,15).
At a constant SV, an increase of PAWP has a more
pronounced effect on systolic PAP and mPAP than diastolic
PAP (Fig. 2). This impact is even greater when SV
increases. As a result, TPG is inﬂuenced by all determinants
of mPAP, including ﬂow, resistance, and left heart ﬁlling
pressure (11,15). In contrast, diastolic PAP when compared
with systolic pulmonary artery pressure and mPAP is less
inﬂuenced by PAWP, which might be explained by a lower
sensitivity to vessel distensibility (10,11). This is illustrated
by a less steep slope of the diastolic pulmonary artery pres-
sure/PAWP line compared with the same relationship with
systolic and mPAP at any level of SV (Fig. 2). When re-
ported as pressure differences, DPD seems to best approach
the characteristics required to determine PVD.
In normal subjects, DPD lies in the 1-mmHg to 3-mmHg
range, and in patients evaluated for cardiac disease
(excluding shunts), the DPD remains 5 mm Hg in most
cases (11,16).
In a retrospective study, 406 patients with PVR 200
dynes/s/cm5 were compared with 406 subjects presenting
with PVR <200 dynes/s/cm5. Patients were catheterized
for evaluation of HF (n ¼ 367), valvular regurgitation
(n ¼ 177), valvular stenosis (n ¼ 244), and possible
constrictive/restrictive physiology (n ¼ 24) (16). In patients
with PVR <200, PAPd and PAWP were similar, and
Figure 2 Effect of PAWP and SV on Pulmonary Pressures
Pulmonary artery wedge pressure (PAWP) is transmitted in a 1:1 ratio to diastolic pulmonary artery pressure (dPpa) and PAWP, both pressures being within a 3-mm Hg range. If
PAWP is directly transmitted to dPpa, there is a non-proportional increase in systolic (sPpa) and mean (mPpa) pulmonary artery pressure, depending on (SV) (left graph). The
transpulmonary gradient (TPG) increases, but the dPpa-PAWP gradient is independent of both PAWP and SV (right graph). If dPpa increases more than PAWP, the TPG increases.
The dPpa-Ppw gradient increases linearly but slightly with PAWP but is independent of SV. Reproduced with permission from Naeije et al. (11).
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D103DPD remained 5 mm Hg in 94% of the cases. When
PVR increased, approximately one-half hadDPD>5mmHg;
however, a PAP 40 mm Hg was associated with an
increased DPD >5 mm Hg in <20%.
This suggests that, when PH develops in heart diseases,
DPD increases >5 mm Hg in one-half of the cases and that
the increase in PAPd is somehow unrelated to the changes
in PAWP. Therefore, the DPD might be seen as a potential
marker of changes in the pulmonary circulation.
The role of the DPD in predicting outcome has recently
been explored in a large cohort of patients referred to
a single center for PH evaluation (17). In this retrospective
study on 3,107 patients, the population was separated
according to the current deﬁnition of “passive” versus
“reactive” PH, the latter being referred to as “out-of-
proportion” PH. Pulmonary hypertension due to LHD
accounted for 35% of all cases of PH. More than one-half
(55%) presented passive with PH-LHD, and 45% had
“reactive” PH. By receiver-operating characteristic analysis,
a DPD 7 mm Hg has been identiﬁed to independently
predict outcome. The authors subsequently deﬁned “out-
of-proportion” PH as a TPG >12 mm Hg and a DPD
>7 mm Hg, which represented 16% of the patients with
PH-LHD. Patients with a TPG >12 mm Hg and a
DPD 7 mm Hg had a worse median survival (78 months)
compared with patients who presented with a DPD
<7 mm Hg (101 months; p ¼ 0.010). Survival in patients
with an elevated TPG and DPD was similar to that re-
ported for PAH (class I) patients. In addition, an elevated
DPD was associated with more advanced pulmonary
vascular remodeling in a small sample of patients who
had lung biopsies. However, this study has importantlimitations, including its retrospective nature, a bias in the
population with patients presenting a negative DPD, and
the unknown number of patients with a TPG <12 mm Hg
but a DPD 7 mm Hg.
Recommendations. The term “out-of-proportion” PH
should be abandoned in patients with post-capillary hemo-
dynamic status, while recognizing the importance of
describing the presence of a pre-capillary component in
some cases of PH-LHD, without further implications in
terms of reactivity, remodeling, or changes in the pulmonary
circulation that cannot be assessed clinically.
We propose 2 types of PH-LHD, on the basis of the
level of the DPD: “isolated post-capillary PH” (PAWP
>15 mm Hg and DPD <7 mm Hg) and “combined post-
capillary PH and pre-capillary PH” (PAWP >15 mm Hg
and DPD 7 mm Hg. Cutoff values and the deﬁnition are
shown in Table 2.
Gaps in evidence. Although based on a strong patho-
physiological reasoning, the respective value of the TPG
and the DPD should be further explored, including their
role in predicting outcome. Multicenter data collection
and analysis of established databases might be helpful to
address the issue in an acceptable timeframe. A joint
initiative with the International Society for Heart and
Lung Transplantation might help to establish a common
nomenclature and develop this in the speciﬁc context of
heart transplantation and LV assist devices. This pop-
ulation is of interest, because patients with advanced HF
are at much higher risk of presenting with a pre-capillary
component of their PH.
The standardization and the relevance of testing the
vasoreactivity of PH-LHD could be addressed in the context
Table 2 Proposed Deﬁnition and Classiﬁcation of PH-LHD
Terminology PAWP Diastolic PAP – PAWP
Isolated post-capillary PH >15 mm Hg <7 mm Hg
Combined post-capillary
and pre-capillary PH
>15 mm Hg 7 mm Hg
Hemodynamic measurements are taken under resting conditions.
LHD ¼ left heart disease; other abbreviations as in Table 1.
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described proposals. In line with the previous comments,
this topic is of critical importance in the context of heart
transplantation and mechanical circulatory support. Its
relevance in other ﬁelds of cardiology (i.e., valvular heart
disease, management of HF) is unknown.
The importance of ﬂuid loading and exercise in uncov-
ering PH due to LHD requires standardization and vali-
dation. Recent advances suggest that these tools might play
a role in the differential diagnosis of PH, which has been
discussed elsewhere and is beyond the scope of this
manuscript.
The importance of the failing RV in the context of PH-
LHD should be further explored. We believe that there
might be a spectrum of clinical phenotypes in PH-LHD
that might evolve from one to the other, from isolated
post-capillary PH with little effect on the RV to more
advanced disease where the failing RV is the key determi-
nant of outcome.
Treatment Insights
The primary goal of therapy of PH-LHD must be to
improve global management of the underlying condition
before considering speciﬁc measures to treat PH. This
includes repair of valvular heart disease and aggressive
therapy for HF with reduced systolic function (18). Some
patients might also beneﬁt from nonspeciﬁc vasodilators
such as nitrates and hydralazine, although evidence sup-
porting this strategy is limited (18). In severe HF, opti-
mizing volume status is of critical importance and might
require invasive monitoring (19). In addition, the implan-
tation of an LV assist device has been shown to lower
pulmonary pressures through LV unloading without
increasing the risk of post-implantation RV failure (20,21).
Risk factors for cardiovascular diseases and features of the
metabolic syndrome should be controlled (18). Concomitant
disorders leading to PH should be identiﬁed and treated,
including chronic obstructive pulmonary disease, sleep apnea
syndrome, and pulmonary embolism. In contrast, there is no
strong evidence-based recommendation for the treatment
for HF-pEF (18).
The potential use of PAH therapies in PH-LHD is based
on a sound pathobiological rationale. In patients with HF,
endothelial dysfunction has been proposed as a cause of PH
and hence as a target for treatment (14), supported by the
presence of increased endothelin 1 activity (22,23) andimpaired NO-dependent vasodilation (24). In addition,
direct LV myocardial effects might be more important
in PH-LHD. For example, endothelin 1 has positive
myocardial inotropic and lusitropic effects that might be
blocked by receptor antagonists. In contrast, inhibition of
phosphodiesterase type 5 (PDE5) attenuates LV remodeling
and improves vascular, renal, and neuroendocrine function
(25–27).
The rationale to use PAH therapies in PH-LHD
has been supported by acute or short-term studies using
prostanoids, endothelin receptor antagonists, and PDE5
inhibitors. Most of these studies consistently reported
improvements in hemodynamic status, exercise capacity, and
symptoms (28). However, the methodology (small sample
size, single-center, unclear or no randomization process)
does not provide enough evidence to support the use of
these drugs in clinical management of patients.
Clinical trialswithprostanoids andendothelin-1 antagonists.
Several randomized controlled trials (RCTs) (Table 3) have
been conducted with PAH-approved therapies (bosentan
[29,30], epoprostenol [31]) or drugs acting on a pathway
involved in the development of PH (darusentan [32,33]).
These studies have the following in common: 1) almost all
studies were performed in HF with systolic dysfunction,
leading to disappointing results; 2) few required optimization
of patient volume status before initiating therapy, which
potentially led to drug-induced adverse events; 3) patients with
valvular heart diseases were excluded; and 4) none of the studies
stratiﬁed patients for the presence of PH, although some re-
ported on invasive hemodynamic status (31,33). The results of
these trials in HF were all negative (Table 3). Two RCTS
(with epoprostenol [31] and high doses of bosentan [29]) had
to be terminated before completion, due to either a trend
toward higher mortality rate (31) or increased side effects (29)
observed in the treated group.
Two RCTs assessed the safety and efﬁcacy of bosentan on
outcome in patients with systolic dysfunction (29,30). The
REACH 1 (Research on Endothelin Antagonism in
Chronic Heart Failure) trial (29) was interrupted due to an
elevated rate of liver function test abnormalities, likely due to
the high dose of bosentan used in the trial (500 mg bid).
The second trial failed to demonstrate a beneﬁt on mortality
and hospital stay (30).
Two RCTs assessed the safety and efﬁcacy of darusentan
on invasive hemodynamic status (33) and outcome (32) in
HF with systolic dysfunction. Although the study drug
seemed to increase CO but not pulmonary capillary wedge
pressure (PCWP) (33), it failed to reach the primary
endpoint of decreasing clinical events and improving
magnetic resonance imaging-derived indexes of LV func-
tion (32).
Clinical trials with PDE5 inhibitors. Before their use as
part of the treatment regimen of HF, PDE5 inhibitors had
been used to treat erectile dysfunction, with an encouraging
safety proﬁle (34). Acutely, sildenaﬁl 25 to 50 mg has
been shown to decrease PVR in the pre-transplant setting
Table 3 Completed RCTs Using Prostanoids and Endothelin Receptor Antagonists in HF
Drug/Author
Year Study Acronym (Ref. #) Patients Design
Primary
Endpoint Results
Epoprostenol
Califf 1996
FIRST (31) n ¼ 471
Severe HF
1:1 randomization
event-driven
mean dose
4 ng/kg/min
Survival Early termination (trend to decreased
survival in treated group)
Bosentan
Packer
REACH-1 (29) n ¼ 174
Severe HF
2:1 randomization
26-week duration
500 mg bid
Change in clinical state Early termination (drug-induced ﬂuid
retention in the treated group)
Kalra 2002 ENABLE (30) n ¼ 1,613
Severe HF
1:1 randomization
18-month duration
125 mg bid
Mortality þ hospital stays No effect
Darusentan
Lüscher 2002
HEAT (33) n ¼ 179
NYHA III
3:1 randomization
3-week duration
doses of 30, 100,
300 mg
Hemodynamic (changes
in PAWP/CO)
Increased CO
No change in PAWP
Anand 2004 EARTH (32) n ¼ 642
NYHA II–IV
5:1 randomization
6-month duration
doses 10, 25, 50,
100, 300 mg
LV changes by MRI þ
clinical events
No effect
See text for references.
CO ¼ cardiac output; HF ¼ heart failure; LV ¼ left ventricular; MRI ¼ magnetic resonance imaging; NYHA ¼ New York Heart Association functional class; PAWP ¼ pulmonary artery wedge pressure;
RCT ¼ randomized controlled trial.
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D105(35–37), to improve hemodynamic variables at rest (34,38)
and exercise (38) and to improve peak oxygen consumption
(VO2) (34,38–40). The vasodilator capacities of sildenaﬁl
seem to be superior to prostaglandin E1. In a case-controlled
prospective study, 22 patients with PVR>200 dynes/s/cm5
received a single dose of 40 mg of sildenaﬁl, compared
with 24 matched control subjects (41). Acute administra-
tion of sildenaﬁl was associated with a greater improvement
in PVR and compliance compared with prostaglandin E1.
Chronic administration of sildenaﬁl has also been shown
to improve pulmonary hemodynamic status before trans-
plantation (37).
In a placebo-controlled study performed in patients with
decreased LVEF, sildenaﬁl has been shown to improve
hemodynamic status and exercise tolerance after 12 weeks at
a dose of 25 to 75 mg tid (38). The 20% decrease in PVR
was mostly accounted for by an improvement in CO,
whereas mPAP remained unchanged. Similar improvements
in exercise tolerance were sustained up to 6 months with
sildenaﬁl 50 mg tid (42).
Although encouraging, the results of these RCTs should
be treated with caution, because the studies were single-
center and used a range of doses of sildenaﬁl (from 25 to
75 mg tid) that were consistently higher than the doses
approved to treat PAH.
Two multicenter clinical trials in PH-LHD are currently
underway (Table 4), with sildenaﬁl (NCT01616381) (43)
and tadalaﬁl (NCT01910389). Although these trials plan
to include a well-deﬁned population with PH due to systolic
HF, the absence of RHC validation of PH might represent
a signiﬁcant limitation.
Guanylate cyclase stimulators. Riociguat is a novel soluble
guanylate cyclase (sGC) stimulator that sensitizes sGC to
endogenous NO and directly stimulates sGC independentlyof NO (44). Its vasodilatory effects might be associated with
anti-ﬁbrotic, anti-proliferative, and anti-inﬂammatory
effects (44). Riociguat has recently been shown to improve
6-min walking distance in PAH (45) and chronic throm-
boembolic pulmonary hypertension (46).
In a multicentric placebo-controlled trial (47), 201
patients with PH due to systolic HF were randomized in 4
arms comparing 3 doses of riociguat (0.5, 1, and 2 mg tid)
with placebo during 16 weeks. No effect on the primary
endpoint (a change in mPAP after 16 weeks) was observed
at any dose of riociguat compared with placebo.
A proof-of concept study to test the effects of riociguat in
patients with PH associated with diastolic dysfunction
(NCT01172756) has recently been completed, but results
are not yet available (Table 4).
HF with preserved EF. Heart failure with preserved ejec-
tion fraction (HF-pEF) is a common cause of PH (1,2,7,9),
and the latter is also associated with a worse outcome (7). In
contrast with systolic HF, exposure of patients with HF-
pEF to vasodilators is associated with a greater blood pres-
sure reduction, a modest increase in CO, and a greater
likelihood to decrease SV (48). Thus, there are fundamental
differences in the 2 HF phenotypes, and this suggests
that more pathophysiologically targeted therapies are needed
in this setting. Therefore, it is anticipated that PAH ther-
apies might have a different effect in patients with HF-pEF
compared with other forms of HF.
Data on the use of PAH therapies in the context of HF-
pEF with or without PH are scarce.
The effects of sildenaﬁl on exercise capacity and
clinical status have been studied in a recently published pha-
se II trial (49). A total of 216 patients with HF-pEF
were randomized to receive sildenaﬁl (n ¼ 113) or placebo
(n ¼ 103) administered orally at 20 mg tid for 12 weeks,
Table 4 Current Phase II/III Placebo-Controlled Randomized Trials in PH With LHD
Drug
Trial (Ref. #)
Trial Number n Start End Duration
Primary
Endpoint
Secondary
Endpoints
HF With Reduced EF
Riociguat
LEPHT (47)
(BAY63-2521)
201 Published (50) 16 W Mean PAP AE, PK, PVR, NT-pro BNP
Tadalaﬁl
PITCH-HF
(NCT01910389)
2102 Up to 54 months Time to CV death or 1st HF
hospital stay
Biomarkers, exercise
capacity, QoL
Sildenaﬁl
Sil-HF (43)
(NCT01616381)
210 9/2012 6/2014 24 W Patient Global Assessment
and 6MWT
Qol, Kansas City
questionnaire, AE
HF With Preserved EF
Riociguat
DILATE
(BAY63-2521)
48 Recruitment completed 16 W mPAP AE, PK, PVR, NT-pro BNP
Available from ClinicalTrials.gov; accessed July 27, 2013.
AE ¼ adverse events; CV ¼ cardiovascular; NT-proBNP ¼ N-terminal pro–B-type natriuretic peptide; PK¼ pharmacokinetics; PVR¼ pulmonary vascular resistance; QoL¼ quality of life; 6MWT¼ 6-min walk
test; other abbreviations as in Table 1.
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D106followed by 60 mg tid for 12 weeks. In line with previous
RCTs inHFdue to reducedEF, there was no stratiﬁcation for
PH. After 24 weeks on a therapy regimen, there was no
difference between groups in the primary endpoint, the
change in peak VO2. In addition, there was no difference in
other relevant secondary endpoints, including outcome
measurements.
In 1 placebo-controlled study that was performed in
patients with PH induced by HF-pEF, sildenaﬁl 50 mg tid
improved exercise capacity and hemodynamic status after 6
months, with beneﬁcial effects up to 1 year (50).
Recommendations. Vasoreactivity testing in PH-LHD
should not be performed with selective pulmonary vasodi-
lators (e.g., IV prostacyclin) in patients with PCWP
>15 mm Hg, due to the risk of increased PCWP and
pulmonary edema. The role of vasoreactivity testing remains
to be explored further.
There is no new evidence supporting the use of PAH
therapies in PH-LHD, due to the absence of studies
speciﬁcally stratifying patients for PH and/or targeting this
speciﬁc condition.
RCTs in PH due to left heart diseases. The history of
trials to treat PH-LHD has yielded little evidence of
clinical efﬁcacy. In addition, much of the available evi-
dence applies to HF (in which many drugs efﬁcacious for
PAH have failed) and without speciﬁc focus of the
subgroup of patients with PH-LHD (for which data are
scarce). Many reasons might explain why this ﬁeld seems
to be stagnant. Firstly, the population of HF is more
heterogeneous than in PAH and more male, with older
patients, and extensive background therapy resulting in
complex polypharmacy. Secondly, the target population
has not been properly deﬁned. If all patients meeting
the deﬁnition of PH-LHD were to be included in a trial,
heterogeneity would be further increased by mixingpatients with isolated post-capillary PH and patients with
combined post-capillary with a pre-capillary component.
The latter is felt to be the population of interest for future
studies. Finally, the question of the most appropriate
endpoint to assess for any intervention in the setting of
PH-LHD is critical. It is acceptable and necessary for
a proof-of-concept to assess safety ﬁrst together with
evidence of an efﬁcacy signal based on a measurable clin-
ical, exercise capacity, and/or hemodynamic improvement
only. This would prompt larger, event-driven RCT with
robust endpoints in event-driven trials for regulatory
approval.
Recommendations for RCTs. POPULATION. Patients with
PH due to HF-pEF and PH due to HF with reduced EF
should be studied separately. Patients with uncorrected
valvular heart diseases should be excluded. Patients with
corrected valvular heart diseases might be studied as well.
Patients should be on optimal regimens of HF therapy
and ﬂuid balance before randomization.
Patients with combined post-capillary and pre-capillary
PH should represent the target population. Recruitment
should be based on RHC, although pre-screening by
echocardiography might be considered.
ENDPOINT. A proof-of-concept study, including a placebo
arm, should be conducted ﬁrst to assess safety and record an
efﬁcacy signal (preferably hemodynamic and/or exercise
capacity assessment). The latter could be either a change in
DPD and/or peak VO2 or ventilatory efﬁciency and/or
increase in 6-min walking distance.
The population should ideally be similar in proof-
of-concept and phase III studies (i.e., identiﬁed by
invasive hemodynamic status, performed in the same
clinical setting in patients on a regiment of optimized
and stable therapy), although this approach might be
challenging.
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a composite endpoint should be considered (a combination
of cardiovascular mortality, hospital stay for worsening HF,
and/or PH).
CHALLENGES. An invasive approach for recruiting in these
trials is challenging, because many HF patients are not
necessarily seen in highly specialized PH centers. It is of
critical importance to properly characterize patients who
might best beneﬁt from the intervention.
In addition, invasive hemodynamic assessments are not
part of standard of care in HF irrespective of EF, and right
heart catheterization is even discouraged (18,19).
Recruitment might be delayed by the increasing off-label
use of PDE5 inhibitors, the difﬁculties in performing
collaborative studies between PH and HF centers, and
potential exclusion of patients due to a high risk of drug-
drug interaction.
Management of PH in LHD remains an unmet medical
need lacking in an evidence-based approach. We believe that
the revised deﬁnition of the nomenclature will help clini-
cians to better identify this growing population of patients
that deserves special attention. Although still provisional,
the proposed deﬁnition should be further validated by using
clinical registries. There is currently no approved therapy for
PH due to LHD. Nevertheless, we propose ideas that might
help investigators to embark on clinical trials that might help
to advance the ﬁeld of PH in the near future.
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